nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—DRD2—Gilles de la Tourette syndrome	0.466	0.564	CbGaD
Zuclopenthixol—HTR2A—Gilles de la Tourette syndrome	0.36	0.436	CbGaD
Zuclopenthixol—HTR2A—autonomic nervous system—Gilles de la Tourette syndrome	0.00394	0.129	CbGeAlD
Zuclopenthixol—HTR6—nervous system—Gilles de la Tourette syndrome	0.00172	0.0564	CbGeAlD
Zuclopenthixol—DRD5—nervous system—Gilles de la Tourette syndrome	0.00167	0.055	CbGeAlD
Zuclopenthixol—HTR6—central nervous system—Gilles de la Tourette syndrome	0.00166	0.0543	CbGeAlD
Zuclopenthixol—DRD5—central nervous system—Gilles de la Tourette syndrome	0.00161	0.0529	CbGeAlD
Zuclopenthixol—DRD1—midbrain—Gilles de la Tourette syndrome	0.00156	0.0511	CbGeAlD
Zuclopenthixol—HTR6—brain—Gilles de la Tourette syndrome	0.00131	0.0431	CbGeAlD
Zuclopenthixol—DRD5—brain—Gilles de la Tourette syndrome	0.00128	0.042	CbGeAlD
Zuclopenthixol—DRD1—nervous system—Gilles de la Tourette syndrome	0.00128	0.042	CbGeAlD
Zuclopenthixol—DRD1—central nervous system—Gilles de la Tourette syndrome	0.00123	0.0404	CbGeAlD
Zuclopenthixol—DRD1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00102	0.00763	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000996	0.00747	CbGpPWpGaD
Zuclopenthixol—HTR6—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000994	0.00745	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00098	0.00735	CbGpPWpGaD
Zuclopenthixol—DRD1—brain—Gilles de la Tourette syndrome	0.000978	0.0321	CbGeAlD
Zuclopenthixol—HRH1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000978	0.00734	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00096	0.0072	CbGpPWpGaD
Zuclopenthixol—DRD1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000946	0.00709	CbGpPWpGaD
Zuclopenthixol—DRD2—midbrain—Gilles de la Tourette syndrome	0.00092	0.0302	CbGeAlD
Zuclopenthixol—DRD1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000918	0.00689	CbGpPWpGaD
Zuclopenthixol—DRD5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000902	0.00676	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000892	0.00669	CbGpPWpGaD
Zuclopenthixol—DRD1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000855	0.00642	CbGpPWpGaD
Zuclopenthixol—DRD2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00085	0.00637	CbGpPWpGaD
Zuclopenthixol—DRD2—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.000845	0.00634	CbGpPWpGaD
Zuclopenthixol—HTR2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000836	0.00627	CbGpPWpGaD
Zuclopenthixol—HRH1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000834	0.00626	CbGpPWpGaD
Zuclopenthixol—HTR6—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000828	0.00621	CbGpPWpGaD
Zuclopenthixol—DRD2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000825	0.00619	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000818	0.00614	CbGpPWpGaD
Zuclopenthixol—HTR2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000811	0.00609	CbGpPWpGaD
Zuclopenthixol—HRH1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00081	0.00607	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000795	0.00596	CbGpPWpGaD
Zuclopenthixol—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.000771	0.0253	CbGeAlD
Zuclopenthixol—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00076	0.0057	CbGpPWpGaD
Zuclopenthixol—DRD2—nervous system—Gilles de la Tourette syndrome	0.000756	0.0248	CbGeAlD
Zuclopenthixol—HTR2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000756	0.00567	CbGpPWpGaD
Zuclopenthixol—HRH1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000754	0.00566	CbGpPWpGaD
Zuclopenthixol—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.000743	0.0244	CbGeAlD
Zuclopenthixol—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00074	0.00555	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000738	0.00554	CbGpPWpGaD
Zuclopenthixol—DRD2—central nervous system—Gilles de la Tourette syndrome	0.000728	0.0239	CbGeAlD
Zuclopenthixol—DRD2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000714	0.00536	CbGpPWpGaD
Zuclopenthixol—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.000713	0.0234	CbGeAlD
Zuclopenthixol—DRD1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000713	0.00535	CbGpPWpGaD
Zuclopenthixol—HTR2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000703	0.00527	CbGpPWpGaD
Zuclopenthixol—HRH1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000701	0.00526	CbGpPWpGaD
Zuclopenthixol—HTR6—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000696	0.00522	CbGpPWpGaD
Zuclopenthixol—DRD2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000693	0.0052	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000688	0.00516	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000688	0.00516	CbGpPWpGaD
Zuclopenthixol—HTR2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000682	0.00512	CbGpPWpGaD
Zuclopenthixol—HRH1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000681	0.00511	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000668	0.00501	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000639	0.00479	CbGpPWpGaD
Zuclopenthixol—HTR2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000635	0.00477	CbGpPWpGaD
Zuclopenthixol—HRH1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000634	0.00476	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000622	0.00467	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000621	0.00465	CbGpPWpGaD
Zuclopenthixol—HTR2A—midbrain—Gilles de la Tourette syndrome	0.000607	0.0199	CbGeAlD
Zuclopenthixol—DRD1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000599	0.00449	CbGpPWpGaD
Zuclopenthixol—HRH1—nervous system—Gilles de la Tourette syndrome	0.000597	0.0196	CbGeAlD
Zuclopenthixol—ADRA1A—brain—Gilles de la Tourette syndrome	0.00059	0.0193	CbGeAlD
Zuclopenthixol—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.000586	0.0192	CbGeAlD
Zuclopenthixol—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000578	0.00434	CbGpPWpGaD
Zuclopenthixol—DRD2—brain—Gilles de la Tourette syndrome	0.000578	0.019	CbGeAlD
Zuclopenthixol—HRH1—central nervous system—Gilles de la Tourette syndrome	0.000575	0.0189	CbGeAlD
Zuclopenthixol—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.000565	0.0185	CbGeAlD
Zuclopenthixol—DRD2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000538	0.00404	CbGpPWpGaD
Zuclopenthixol—HRH1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000528	0.00396	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000518	0.00389	CbGpPWpGaD
Zuclopenthixol—HTR2A—nervous system—Gilles de la Tourette syndrome	0.000499	0.0164	CbGeAlD
Zuclopenthixol—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000482	0.00361	CbGpPWpGaD
Zuclopenthixol—HTR2A—central nervous system—Gilles de la Tourette syndrome	0.00048	0.0158	CbGeAlD
Zuclopenthixol—HRH1—brain—Gilles de la Tourette syndrome	0.000456	0.015	CbGeAlD
Zuclopenthixol—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000454	0.0149	CbGeAlD
Zuclopenthixol—DRD2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000452	0.00339	CbGpPWpGaD
Zuclopenthixol—ADRA2A—brain—Gilles de la Tourette syndrome	0.000448	0.0147	CbGeAlD
Zuclopenthixol—HRH1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000444	0.00333	CbGpPWpGaD
Zuclopenthixol—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000437	0.0144	CbGeAlD
Zuclopenthixol—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000436	0.00327	CbGpPWpGaD
Zuclopenthixol—Flupentixol—DRD2—Gilles de la Tourette syndrome	0.000411	0.0435	CrCbGaD
Zuclopenthixol—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000405	0.00304	CbGpPWpGaD
Zuclopenthixol—Domperidone—DRD3—Gilles de la Tourette syndrome	0.0004	0.0423	CrCbGaD
Zuclopenthixol—HTR2A—brain—Gilles de la Tourette syndrome	0.000381	0.0125	CbGeAlD
Zuclopenthixol—HTR2A—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000371	0.00278	CbGpPWpGaD
Zuclopenthixol—Acetophenazine—DRD2—Gilles de la Tourette syndrome	0.000365	0.0386	CrCbGaD
Zuclopenthixol—HTR2A—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00036	0.0027	CbGpPWpGaD
Zuclopenthixol—CYP2D6—brain—Gilles de la Tourette syndrome	0.000347	0.0114	CbGeAlD
Zuclopenthixol—DRD5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000327	0.00245	CbGpPWpGaD
Zuclopenthixol—Flupentixol—HTR2A—Gilles de la Tourette syndrome	0.000318	0.0336	CrCbGaD
Zuclopenthixol—DRD5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000317	0.00238	CbGpPWpGaD
Zuclopenthixol—Nefazodone—SLC6A3—Gilles de la Tourette syndrome	0.000309	0.0327	CrCbGaD
Zuclopenthixol—DRD5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000296	0.00222	CbGpPWpGaD
Zuclopenthixol—Amoxapine—DRD4—Gilles de la Tourette syndrome	0.000294	0.0311	CrCbGaD
Zuclopenthixol—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00028	0.0021	CbGpPWpGaD
Zuclopenthixol—Domperidone—DRD2—Gilles de la Tourette syndrome	0.000277	0.0293	CrCbGaD
Zuclopenthixol—Prochlorperazine—DRD3—Gilles de la Tourette syndrome	0.000275	0.0291	CrCbGaD
Zuclopenthixol—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000272	0.00204	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000265	0.00199	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000257	0.00193	CbGpPWpGaD
Zuclopenthixol—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000253	0.0019	CbGpPWpGaD
Zuclopenthixol—Amoxapine—DRD3—Gilles de la Tourette syndrome	0.000253	0.0268	CrCbGaD
Zuclopenthixol—HTR6—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000252	0.00189	CbGpPWpGaD
Zuclopenthixol—Fluphenazine—DRD3—Gilles de la Tourette syndrome	0.000249	0.0263	CrCbGaD
Zuclopenthixol—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000245	0.00184	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00024	0.0018	CbGpPWpGaD
Zuclopenthixol—Amoxapine—SLC6A3—Gilles de la Tourette syndrome	0.000236	0.0249	CrCbGaD
Zuclopenthixol—Loxapine—DRD4—Gilles de la Tourette syndrome	0.000229	0.0243	CrCbGaD
Zuclopenthixol—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000228	0.00171	CbGpPWpGaD
Zuclopenthixol—Chlorprothixene—DRD3—Gilles de la Tourette syndrome	0.000227	0.024	CrCbGaD
Zuclopenthixol—Quetiapine—DRD4—Gilles de la Tourette syndrome	0.000224	0.0237	CrCbGaD
Zuclopenthixol—DRD1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000217	0.00163	CbGpPWpGaD
Zuclopenthixol—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000216	0.00162	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000213	0.0016	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000211	0.00158	CbGpPWpGaD
Zuclopenthixol—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00021	0.00157	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000207	0.00155	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000207	0.00155	CbGpPWpGaD
Zuclopenthixol—Thioproperazine—DRD2—Gilles de la Tourette syndrome	0.000203	0.0214	CrCbGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.0002	0.0015	CbGpPWpGaD
Zuclopenthixol—Thiothixene—DRD2—Gilles de la Tourette syndrome	0.000199	0.0211	CrCbGaD
Zuclopenthixol—Pipotiazine—DRD2—Gilles de la Tourette syndrome	0.000199	0.0211	CrCbGaD
Zuclopenthixol—Loxapine—DRD3—Gilles de la Tourette syndrome	0.000198	0.0209	CrCbGaD
Zuclopenthixol—DRD1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000196	0.00147	CbGpPWpGaD
Zuclopenthixol—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000195	0.00147	CbGpPWpGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000194	0.00146	CbGpPWpGaD
Zuclopenthixol—Quetiapine—DRD3—Gilles de la Tourette syndrome	0.000193	0.0204	CrCbGaD
Zuclopenthixol—DRD5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000193	0.00145	CbGpPWpGaD
Zuclopenthixol—Clozapine—DRD4—Gilles de la Tourette syndrome	0.000192	0.0204	CrCbGaD
Zuclopenthixol—Prochlorperazine—DRD2—Gilles de la Tourette syndrome	0.00019	0.0202	CrCbGaD
Zuclopenthixol—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000186	0.0014	CbGpPWpGaD
Zuclopenthixol—Loxapine—SLC6A3—Gilles de la Tourette syndrome	0.000184	0.0195	CrCbGaD
Zuclopenthixol—Chlorpromazine—DRD4—Gilles de la Tourette syndrome	0.000181	0.0192	CrCbGaD
Zuclopenthixol—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000181	0.00135	CbGpPWpGaD
Zuclopenthixol—Nefazodone—HTR2A—Gilles de la Tourette syndrome	0.000178	0.0188	CrCbGaD
Zuclopenthixol—DRD5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000177	0.00133	CbGpPWpGaD
Zuclopenthixol—DRD2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000177	0.00132	CbGpPWpGaD
Zuclopenthixol—Amoxapine—DRD2—Gilles de la Tourette syndrome	0.000175	0.0185	CrCbGaD
Zuclopenthixol—Fluphenazine—DRD2—Gilles de la Tourette syndrome	0.000172	0.0182	CrCbGaD
Zuclopenthixol—DRD2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000171	0.00129	CbGpPWpGaD
Zuclopenthixol—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000168	0.00126	CbGpPWpGaD
Zuclopenthixol—Clozapine—DRD3—Gilles de la Tourette syndrome	0.000166	0.0176	CrCbGaD
Zuclopenthixol—HTR6—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000165	0.00123	CbGpPWpGaD
Zuclopenthixol—Trazodone—HTR2A—Gilles de la Tourette syndrome	0.000164	0.0174	CrCbGaD
Zuclopenthixol—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000164	0.00123	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000161	0.00121	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000161	0.00121	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00016	0.0012	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00016	0.0012	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000159	0.00119	CbGpPWpGaD
Zuclopenthixol—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000158	0.00119	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000158	0.00118	CbGpPWpGaD
Zuclopenthixol—Chlorprothixene—DRD2—Gilles de la Tourette syndrome	0.000157	0.0166	CrCbGaD
Zuclopenthixol—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000157	0.00117	CbGpPWpGaD
Zuclopenthixol—Thioproperazine—HTR2A—Gilles de la Tourette syndrome	0.000157	0.0166	CrCbGaD
Zuclopenthixol—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000156	0.00117	CbGpPWpGaD
Zuclopenthixol—Chlorpromazine—DRD3—Gilles de la Tourette syndrome	0.000156	0.0165	CrCbGaD
Zuclopenthixol—Pipotiazine—HTR2A—Gilles de la Tourette syndrome	0.000154	0.0163	CrCbGaD
Zuclopenthixol—Thiothixene—HTR2A—Gilles de la Tourette syndrome	0.000154	0.0163	CrCbGaD
Zuclopenthixol—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000154	0.00115	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000153	0.00115	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000149	0.00112	CbGpPWpGaD
Zuclopenthixol—Thioridazine—DRD2—Gilles de la Tourette syndrome	0.000148	0.0157	CrCbGaD
Zuclopenthixol—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000147	0.0011	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000146	0.00109	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000146	0.00109	CbGpPWpGaD
Zuclopenthixol—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000143	0.00107	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000143	0.00107	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000142	0.00107	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000142	0.00106	CbGpPWpGaD
Zuclopenthixol—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00014	0.00105	CbGpPWpGaD
Zuclopenthixol—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000138	0.00104	CbGpPWpGaD
Zuclopenthixol—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000138	0.00103	CbGpPWpGaD
Zuclopenthixol—Trifluoperazine—DRD2—Gilles de la Tourette syndrome	0.000138	0.0146	CrCbGaD
Zuclopenthixol—DRD1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000138	0.00103	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000138	0.00103	CbGpPWpGaD
Zuclopenthixol—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000137	0.00103	CbGpPWpGaD
Zuclopenthixol—Loxapine—DRD2—Gilles de la Tourette syndrome	0.000137	0.0145	CrCbGaD
Zuclopenthixol—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000136	0.00102	CbGpPWpGaD
Zuclopenthixol—Perphenazine—DRD2—Gilles de la Tourette syndrome	0.000136	0.0144	CrCbGaD
Zuclopenthixol—Amoxapine—HTR2A—Gilles de la Tourette syndrome	0.000135	0.0143	CrCbGaD
Zuclopenthixol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000135	0.00101	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000135	0.00101	CbGpPWpGaD
Zuclopenthixol—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000134	0.00101	CbGpPWpGaD
Zuclopenthixol—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000134	0.001	CbGpPWpGaD
Zuclopenthixol—Quetiapine—DRD2—Gilles de la Tourette syndrome	0.000134	0.0141	CrCbGaD
Zuclopenthixol—Fluphenazine—HTR2A—Gilles de la Tourette syndrome	0.000133	0.0141	CrCbGaD
Zuclopenthixol—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000133	0.000995	CbGpPWpGaD
Zuclopenthixol—HRH1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000132	0.000989	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000131	0.000985	CbGpPWpGaD
Zuclopenthixol—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000129	0.000971	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000128	0.000961	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000126	0.000943	CbGpPWpGaD
Zuclopenthixol—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000125	0.000937	CbGpPWpGaD
Zuclopenthixol—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000125	0.000935	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000122	0.000918	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000122	0.000916	CbGpPWpGaD
Zuclopenthixol—Chlorprothixene—HTR2A—Gilles de la Tourette syndrome	0.000121	0.0128	CrCbGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00012	0.000904	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000118	0.000885	CbGpPWpGaD
Zuclopenthixol—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000118	0.000884	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000117	0.000877	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000116	0.000868	CbGpPWpGaD
Zuclopenthixol—Clozapine—DRD2—Gilles de la Tourette syndrome	0.000115	0.0122	CrCbGaD
Zuclopenthixol—Thioridazine—HTR2A—Gilles de la Tourette syndrome	0.000115	0.0121	CrCbGaD
Zuclopenthixol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000114	0.000853	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000109	0.000821	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000109	0.000817	CbGpPWpGaD
Zuclopenthixol—Chlorpromazine—DRD2—Gilles de la Tourette syndrome	0.000108	0.0114	CrCbGaD
Zuclopenthixol—DRD2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000107	0.000802	CbGpPWpGaD
Zuclopenthixol—Trifluoperazine—HTR2A—Gilles de la Tourette syndrome	0.000106	0.0113	CrCbGaD
Zuclopenthixol—DRD5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000106	0.000797	CbGpPWpGaD
Zuclopenthixol—Loxapine—HTR2A—Gilles de la Tourette syndrome	0.000106	0.0112	CrCbGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000105	0.000789	CbGpPWpGaD
Zuclopenthixol—Perphenazine—HTR2A—Gilles de la Tourette syndrome	0.000105	0.0111	CrCbGaD
Zuclopenthixol—HRH1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000105	0.000788	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000104	0.000782	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000104	0.000779	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000104	0.000779	CbGpPWpGaD
Zuclopenthixol—Quetiapine—HTR2A—Gilles de la Tourette syndrome	0.000103	0.0109	CrCbGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000103	0.000773	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000102	0.000766	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000102	0.000765	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000102	0.000765	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0001	0.00075	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0001	0.00075	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	9.9e-05	0.000742	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.57e-05	0.000718	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.52e-05	0.000714	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.5e-05	0.000712	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.32e-05	0.000699	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	9.3e-05	0.000698	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.3e-05	0.000697	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.3e-05	0.000697	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	9.18e-05	0.000689	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	9.03e-05	0.000677	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.97e-05	0.000673	CbGpPWpGaD
Zuclopenthixol—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.9e-05	0.000667	CbGpPWpGaD
Zuclopenthixol—Clozapine—HTR2A—Gilles de la Tourette syndrome	8.88e-05	0.00939	CrCbGaD
Zuclopenthixol—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.73e-05	0.000655	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.66e-05	0.000649	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.57e-05	0.000643	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	8.45e-05	0.000633	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	8.41e-05	0.000631	CbGpPWpGaD
Zuclopenthixol—Chlorpromazine—HTR2A—Gilles de la Tourette syndrome	8.35e-05	0.00883	CrCbGaD
Zuclopenthixol—HTR6—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	8.2e-05	0.000615	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.01e-05	0.0006	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	7.96e-05	0.000597	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.77e-05	0.000583	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.64e-05	0.000573	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	7.63e-05	0.000572	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.27e-05	0.000545	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.24e-05	0.000543	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.06e-05	0.000529	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	6.93e-05	0.00052	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.77e-05	0.000508	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.65e-05	0.000499	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.57e-05	0.000493	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.53e-05	0.00049	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.46e-05	0.000485	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.27e-05	0.000471	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.06e-05	0.000455	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.04e-05	0.000453	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	5.98e-05	0.000449	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.95e-05	0.000446	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.93e-05	0.000445	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.89e-05	0.000442	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.87e-05	0.00044	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.85e-05	0.000438	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.82e-05	0.000437	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.77e-05	0.000433	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.76e-05	0.000432	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.65e-05	0.000424	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.49e-05	0.000412	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.41e-05	0.000406	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.4e-05	0.000405	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.39e-05	0.000404	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.38e-05	0.000403	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.37e-05	0.000403	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.35e-05	0.000401	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.33e-05	0.0004	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.29e-05	0.000397	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.27e-05	0.000395	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.25e-05	0.000394	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.24e-05	0.000393	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.23e-05	0.000392	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.13e-05	0.000385	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.07e-05	0.00038	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.99e-05	0.000374	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.91e-05	0.000369	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.89e-05	0.000367	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.88e-05	0.000366	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.87e-05	0.000366	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.84e-05	0.000363	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.78e-05	0.000359	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.77e-05	0.000358	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.6e-05	0.000345	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.51e-05	0.000338	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.44e-05	0.000333	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.29e-05	0.000322	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.17e-05	0.000313	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.09e-05	0.000307	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.88e-05	0.000291	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.83e-05	0.000287	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.76e-05	0.000282	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.69e-05	0.000277	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.48e-05	0.000261	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.43e-05	0.000257	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.41e-05	0.000256	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.35e-05	0.000251	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.24e-05	0.000243	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.19e-05	0.000239	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.18e-05	0.000239	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.16e-05	0.000237	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.15e-05	0.000236	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.12e-05	0.000234	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.11e-05	0.000233	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.1e-05	0.000232	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.09e-05	0.000232	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.03e-05	0.000227	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.9e-05	0.000218	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.89e-05	0.000216	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.88e-05	0.000216	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.83e-05	0.000212	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.82e-05	0.000211	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.72e-05	0.000204	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.63e-05	0.000197	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.05e-05	0.000154	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.02e-05	0.000151	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.98e-05	0.000148	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.84e-05	0.000138	CbGpPWpGaD
